Mirae Asset Global ETFs Holdings
SYRE icon

Mirae Asset Global ETFs Holdings’s Spyre Therapeutics SYRE Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
38,439
+2,116
+6% +$154K ﹤0.01% 1010
2026
Q1 		$1.81M Buy
36,323
+1,179
+3% +$44.4K ﹤0.01% 1219
2025
Q4 		$1.15M Buy
35,144
+8,696
+33% +$227K ﹤0.01% 1440
2025
Q3 		$442K Sell
26,448
-3,364
-11% -$54.9K ﹤0.01% 1920
2025
Q2 		$447K Buy
29,812
+2,794
+10% +$41.3K ﹤0.01% 1875
2025
Q1 		$442K Buy
27,018
+4,277
+19% +$89K ﹤0.01% 1939
2024
Q4 		$527K Buy
22,741
+916
+4% +$26.9K ﹤0.01% 1893
2024
Q3 		$639K Buy
21,825
+19,299
+764% +$537K ﹤0.01% 1793
2024
Q2 		$57.4K Buy
+2,526
New +$85.2K ﹤0.01% 2754

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's SYRE Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Spyre Therapeutics (SYRE) stake by 5.8% in Q2 2026, buying an estimated $154K and bringing the position to 38,439 shares worth $3.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

Mirae Asset Global ETFs Holdings first reported a position in SYRE in Q2 2024 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 38,439 shares of Spyre Therapeutics worth $3.42M as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 2,116 Spyre Therapeutics shares in Q2 2026, an estimated $154K.
  • Spyre Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1010 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.